Skip to main content
GLP-1 Drugs Increase Risk of Retinopathy
More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking GLP-1 receptor agonist drugs and diabetic retinopathy. This cohort study of people with type 2 diabetes found a 7% significant increase in risk of diabetic retinopathy with at least 2 prescriptions of a GLP-1 drug given six months apart.
References
Ramsey D, Makwana B, Sourbha D, et al. GLP-1 Receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes. JAMA Network Open. 2025;8(8):e2526321. doi:10.1001/jamanetworkopen.2025.26321
